Skip to main content

InnoCare Granted Clinical Trial Approval For Another Liquid Cancer Drug Candidate In China

InnoCare Pharma, which focuses on the treatment of cancer and autoimmune diseases, will look to further complete its product pipelines with the approval for its novel targeted protein degrader ICP-490.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.